ABSTRACT

Case reports due to toxic myopathy increases with new synthetic statin drugs when compared with the first generation drugs.

Symptoms can vary from mildly elevated CK levels and myalgia to fatal rabdomyolitic syndrome; a rare severe condition.

Our case is a 58 year–old male patient, taking fluvastatin 80 mg/day, a HMG-CoA inhibitor. After 5 weeks of his treatment, he admitted to the hospital with muscle weakness and myalgia, starting from arms and spreading down to the legs.

On laboratory examination CK level in blood was 2625 U/l and in biopsy there was myogenic involvement with necrosis, regeneration and mitochondrial changes. The myopathic involvement resolved clinically, electrophysiologically and on laboratory tests by discontinuation of the drug.

Because of widespread use of statin group drugs, our case is important to follow such patients carefully and regularly.